Genomic determinants of patterns of failure in metachronous oligometastatic castrationsensitive prostate cancer. Journal of Clinical Oncology. 41. 238-238. 10.1200/JCO.2023.41.6 suppl.238.
Philip Sutera, Kim Van der Eecken et al.
The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer. Journal of Clinical Oncology. 41. e17077-e17077. 10.1200/JCO.2023.41.16 suppl.e17077
Tung Hoang, Kim Van der Eecken et al.
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. European Urology. 10.1016/j.eururo.2023.04.025.
Philip Sutera, Kim Van der Eecken et al.
Transcriptomic heterogeneity of metastatic disease timing within metastatic castrationsensitive prostate cancer. Journal of Clinical Oncology. 41. e17083-e17083. 10.1200/JCO.2023.41.16 suppl.e17083
Philip Sutera, Kim Van der Eecken et al.
WSI based prediction of TP53 mutations identifies aggressive disease phenotype in prostate cancer. Cancer Research. 2023 83. LB171-LB171. 10.1158/1538-7445.AM2023-LB171
Marija Pizurica, Kim Van der Eecken et al.
Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer. Cancer Research. 83. IA006-IA006. 10.1158/1538-7445.PRCA2023-IA006
Alexander Wyatt, Kim Van der Eecken et al.
Genomic biomarkers to guide precision radiotherapy in prostate cancer. The Prostate. 82. 10.1002/pros.24373. 2022
Philip Sutera, Kim Van der Eecken et al.
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 115. 10.1016/j.ijrobp.2022.12.006
Philip Sutera, Kim Van der Eecken et al.
Unraveling the genomics underpinnings advanced of prostate cancer. PhD thesis 2022
Kim Van der Eecken
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. Journal of Clinical Oncology. 2022 Oct 10;40(29):3377-3382
Kim Van der Eecken et al.
4MO Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer. Annals of Oncology. 33. S1384. 10.1016/j.annonc.2022.09.005
A.J. Murtha, Kim Van der Eecken et al.
Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer. Cancer Research. 82:41-41. 2022
Evan Warner, Kim Van der Eecken et al.
A transcriptomic signature of AR activity prognosticates development of castrationresistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer.Annals of Oncology. 33. S1174. 10.1016/j.annonc.2022.07.1513.
Phuoc Tran, Kim Van der Eecken et al.
Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer. Cancer research. 10.1158/0008-5472.CAN-22-3113
Marija Pizurica, Kim Van der Eecken et al.
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO PRECISON ONCOLOGY. 2022
Kim Van der Eecken et al.
Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue: a glioma-driven study. VIRCHOWS ARCHIV. 2022; 480:677–86
Kim Van der Eecken et al.
Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review. EUROPEAN UROLOGY ONCOLOGY. 2021;4(6):914–23
Kim Van der Eecken et al.
Combined longitudinal clinical and autopsy phenomic assessment in lethal metastatic prostate cancer: recommendations for advancing precision medicine. EUROPEAN UROLOGY OPEN SCIENCE. 2021;30:47–62
Jasu, Juho, Kim Van der Eecken et al.
The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. EUROPEAN UROLOGY. 2021;80(5):632–40
Deek, Matthew P., Kim Van der Eecken et al.
Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples. BMC MEDICAL GENOMICS. 2020;13(1)
de Schaetzen van Brienen, Kim Van der Eecken et al.
Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. GENOME MEDICINE. 2020;12(1)
Kim Van der Eecken et al.
Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. EUROPEAN UROLOGY. 2019;75(5):707–11. DOI:10.1016/j.eururo.2019.01.009
Sundahl, Nora, Kim Van der Eecken et al.
Oligometastatic prostate cancer : the game is afoot. CANCER TREATMENT REVIEWS. 2019;73:84–90
Lancia, Andrea, Kim Van der Eecken et al.
Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. WORLD JOURNAL OF UROLOGY. 2019;37(12):2557–64..
Dhondt, Bert, Kim Van der Eecken et al.
